Latest Innovation News

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

American West Metals reports significant copper sulphide discoveries and thick mineralised intersections at its Storm Copper Project in Nunavut, Canada, highlighting strong potential for resource expansion.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

FleetPartners delivered a resilient 3Q25 performance with 5% growth in key metrics despite operational challenges from a major system upgrade. A recent $400 million asset-backed securitisation deal also improved funding costs, positioning the company for growth in underpenetrated markets.

Structural Monitoring Systems Plc (SMS) reported a breakout second half of FY25 with a $3.1 million profit after tax, driven by strong operational leverage and strategic growth in avionics. The company secured over US$1 million in new orders from CAL FIRE and advanced FAA certification for its innovative sensor technology.

Generation Development Group reports a transformative FY25 with record Investment Bond sales and successful integration of Evidentia and Lonsec managed accounts, setting the stage for strong growth in FY26.

Iluka Resources has met its full-year zircon-in-concentrate production guidance by mid-2025 while progressing key projects like Balranald and Eneabba amid ongoing global trade uncertainties.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

WAM Global Limited outperformed the MSCI World Index with a 19.4% portfolio gain in FY2025, prompting an increased fully franked dividend of 17.0 cents per share. The company’s strong results reflect strategic positioning amid global market volatility.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.